Judy Johnson

784 total citations
19 papers, 617 citations indexed

About

Judy Johnson is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Judy Johnson has authored 19 papers receiving a total of 617 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Infectious Diseases, 15 papers in Virology and 4 papers in Epidemiology. Recurrent topics in Judy Johnson's work include HIV Research and Treatment (15 papers), HIV/AIDS drug development and treatment (15 papers) and HIV/AIDS Research and Interventions (11 papers). Judy Johnson is often cited by papers focused on HIV Research and Treatment (15 papers), HIV/AIDS drug development and treatment (15 papers) and HIV/AIDS Research and Interventions (11 papers). Judy Johnson collaborates with scholars based in United States, Netherlands and United Kingdom. Judy Johnson's co-authors include John Bartlett, Andrew Hill, Joseph J. Eron, Qiming Liao, Mark S. Shaefer, Daniel R. Kuritzkes, Joseph J. Eron, Allan Rodríguez, Daniel S Berger and A. Philips and has published in prestigious journals such as Annals of Internal Medicine, Clinical Infectious Diseases and The Journal of Infectious Diseases.

In The Last Decade

Judy Johnson

19 papers receiving 578 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Judy Johnson United States	14	459	424	100	92	61	19	617
Claudette Satchell Australia	9	210 0.5×	229 0.5×	52 0.5×	179 1.9×	14 0.2×	14	375
KHF Wong United Kingdom	11	151 0.3×	74 0.2×	119 1.2×	15 0.2×	42 0.7×	29	314
S Staszewski Germany	8	393 0.9×	268 0.6×	96 1.0×	221 2.4×	16 0.3×	25	494
Amit C. Achhra Australia	13	330 0.7×	226 0.5×	89 0.9×	297 3.2×	16 0.3×	26	485
Kassem Bourgi United States	9	330 0.7×	133 0.3×	120 1.2×	284 3.1×	4 0.1×	14	481
Matthijs van Luin Netherlands	10	136 0.3×	57 0.1×	67 0.7×	21 0.2×	10 0.2×	27	260
JM Gatell Spain	13	593 1.3×	354 0.8×	282 2.8×	255 2.8×	11 0.2×	28	805
Mary van den Berg-Wolf United States	11	504 1.1×	334 0.8×	135 1.4×	163 1.8×	7 0.1×	14	645
Roos E. Barth Netherlands	11	231 0.5×	186 0.4×	78 0.8×	161 1.8×	43 0.7×	22	363
Marilyn McMurchie Australia	6	297 0.6×	241 0.6×	84 0.8×	94 1.0×	6 0.1×	11	447

Countries citing papers authored by Judy Johnson

Since Specialization

Citations

This map shows the geographic impact of Judy Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judy Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judy Johnson more than expected).

Fields of papers citing papers by Judy Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judy Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judy Johnson. The network helps show where Judy Johnson may publish in the future.

Co-authorship network of co-authors of Judy Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Judy Johnson. A scholar is included among the top collaborators of Judy Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judy Johnson. Judy Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

1.

Kahn, Marc J., Ronald J. Markert, Judy Johnson, David Owens, & N. Kevin Krane. (2007). Psychiatric Issues and Answers Following Hurricane Katrina. Academic Psychiatry. 31(3). 200–204. 14 indexed citations

2.

O’Donnell, Martin, Clive Kearon, Judy Johnson, et al.. (2007). Brief Communication: Preoperative Anticoagulant Activity after Bridging Low-Molecular-Weight Heparin for Temporary Interruption of Warfarin. Annals of Internal Medicine. 146(3). 184–187. 70 indexed citations

3.

Bartlett, John, Judy Johnson, Néstor Sosa, et al.. (2006). Long-Term Results of Initial Therapy With Abacavir and Lamivudine Combined With Efavirenz, Amprenavir/Ritonavir, or Stavudine. JAIDS Journal of Acquired Immune Deficiency Syndromes. 43(3). 284–292. 56 indexed citations

4.

Gallant, Joel E., Allan Rodríguez, Winkler G. Weinberg, et al.. (2005). Early Virologic Nonresponse to Tenofovir, Abacavir, and Lamivudine in HIV‐Infected Antiretroviral‐Naive Subjects. The Journal of Infectious Diseases. 192(11). 1921–1930. 109 indexed citations

5.

Eron, Joseph J., John Bartlett, Jorge Santana, et al.. (2004). Persistent Antiretroviral Activity of Nucleoside Analogues After Prolonged Zidovudine and Lamivudine Therapy as Demonstrated by Rapid Loss of Activity After Discontinuation. JAIDS Journal of Acquired Immune Deficiency Syndromes. 37(5). 1581–1583. 30 indexed citations

6.

Ruane, Peter, Gary Richmond, Edwin DeJesus, et al.. (2004). Pharmacodynamic Effects of Zidovudine 600 mg Once/Day versus 300 mg Twice/Day in Therapy‐Naïve Patients Infected with Human Immunodeficiency Virus. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 24(3). 307–312. 17 indexed citations

7.

Kessler, Harold A., Judy Johnson, Stephen Follansbee, et al.. (2002). Abacavir Expanded Access Program for Adult Patients Infected with Human Immunodeficiency Virus Type 1. Clinical Infectious Diseases. 34(4). 535–542. 14 indexed citations

8.

Johnson, Judy, et al.. (2002). Lamivudine 300 mg QD Versus Continued Lamivudine 150 mg BID with Stavudine and a Protease Inhibitor in Suppressed Patients. HIV Clinical Trials. 3(5). 361–370. 10 indexed citations

9.

Kost, Rhonda G., Arlene Hurley, Linqi Zhang, et al.. (2001). Open-Label Phase II Trial of Amprenavir, Abacavir, and Fixed-Dose Zidovudine/Lamivudine in Newly and Chronically HIV-1–Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 26(4). 332–339. 9 indexed citations

10.

Talal, Andrew H., Simon Monard, Mika Vesanen, et al.. (2001). Virologic and Immunologic Effect of Antiretroviral Therapy on HIV-1 in Gut-Associated Lymphoid Tissue. JAIDS Journal of Acquired Immune Deficiency Syndromes. 26(1). 1–7. 37 indexed citations

11.

Talal, Andrew H., Simon Monard, Mika Vesanen, et al.. (2001). Virologic and Immunologic Effect of Antiretroviral Therapy on HIV-1 in Gut-Associated Lymphoid Tissue. JAIDS Journal of Acquired Immune Deficiency Syndromes. 26(1). 1–7. 15 indexed citations

12.

Kost, Rhonda G., Arlene Hurley, Linqi Zhang, et al.. (2001). Open-Label Phase II Trial of Amprenavir, Abacavir, and Fixed-Dose Zidovudine/Lamivudine in Newly and Chronically HIV-1–Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 26(4). 332–339. 2 indexed citations

13.

Kuritzkes, Daniel R., David Shugarts, Judy Johnson, et al.. (2000). Emergence of Dual Resistance to Zidovudine and Lamivudine in HIV-1–Infected Patients Treated With Zidovudine Plus Lamivudine as Initial Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 23(1). 26–34. 36 indexed citations

14.

Goff, John S., R. Matthew Reveille, & Judy Johnson. (2000). Treatment of Chronic Hepatitis C with Amantadine. Digestive Diseases and Sciences. 45(7). 1389–1391. 19 indexed citations

15.

Kuritzkes, Daniel R., David Shugarts, Judy Johnson, et al.. (2000). Emergence of Dual Resistance to Zidovudine and Lamivudine in HIV-1–Infected Patients Treated With Zidovudine Plus Lamivudine as Initial Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 23(1). 26–34. 12 indexed citations

16.

Bartlett, John, Paul Berry, Judy Johnson, et al.. (1998). A Placebo‐Controlled Trial of Ranitidine in Patients with Early Human Immunodeficiency Virus Infection. The Journal of Infectious Diseases. 177(1). 231–234. 5 indexed citations

17.

Phillips, Andrew, Joseph J. Eron, John Bartlett, et al.. (1997). Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. AIDS. 11(2). 169–175. 28 indexed citations

18.

Staszewski, Schlomo, Andrew Hill, John Bartlett, et al.. (1997). Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments. AIDS. 11(4). 477–483. 56 indexed citations

19.

Philips, A., et al.. (1996). HIV-1 RNA levels and the development of clinical disease. AIDS. 10(8). 859–866. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact